<DOC>
	<DOCNO>NCT02399202</DOCNO>
	<brief_summary>To characterize pharmacokinetics LCI699 follow single oral dose adult subject various degree impair renal function .</brief_summary>
	<brief_title>A Phase I Study Osilodrostat ( LCI699 ) Healthy Volunteers Subjects With Impaired Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Weight must â‰¥50 kg BMI must 1835 kg/m2 Subjects must stable renal disease without evidence progressive decline renal function ( stable renal disease define significant change , , stable eGFR &lt; 90 mL/min , 12 week prior study entry ) Other renal impairment , subject must stable appropriately manage relative chronic disease ( diabetes hypertension ) History surgical medical condition renal impairment might significantly alter absorption , distribution , metabolism excretion drug . Subjects ongoing alcohol drug abuse within 1 month prior dose evidence abuse indicate laboratory assay conduct screen baseline evaluation . Subjects screen 12lead ECG QTcF &gt; 450 msec male &gt; 460 msec female History diabetes mellitus ( Type 1 2 ) blood glucose &gt; 125 mg/dl screen Subjects potassium level great upper limit normal ( &gt; ULN ) Other protocol define Inclusion/Exclusion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Renal impairment , osilodrostat , LCI699</keyword>
</DOC>